A new analysis by researchers at Mass General, Harvard Medical School, and Georgia Tech indicates that cases of alcohol-related liver disease will rise dramatically in the coming years without drastic steps to reduce high-risk drinking rates.
- A one-year increase in alcohol consumption in the U.S. during the COVID-19 pandemic is estimated to cause 8,000 additional deaths from alcohol-related liver disease, 18,700 cases of liver failure, and 1,000 cases of liver cancer by 2040.
- A sustained increase in alcohol consumption for more than one year could result in 19–35% additional mortality.
BOSTON – Alcohol sales and consumption increased during the start of the COVID-19 pandemic, but the effect of the increase in consumption on population health is not fully understood. In new research published in Hepatology, a team led by investigators at Massachusetts General Hospital (MGH) projected rates of liver disease and associated deaths due to increased alcohol consumption during the COVID-19 pandemic.
Using data from a national survey of U.S. adults on their drinking habits that found that excessive drinking (such as binge drinking) increased by 21% during the COVID-19 pandemic, the scientists simulated the drinking trajectories and liver disease trends in all U.S. adults. They estimated that a one-year increase in alcohol consumption during the COVID-19 pandemic will result in 8,000 additional deaths from alcohol-related liver disease, 18,700 cases of liver failure, and 1,000 cases of liver cancer by 2040. In the short term, alcohol consumption changes due to COVID-19 are expected to cause 100 additional deaths and 2,800 additional cases of liver failure by 2023.
The researchers noted that a sustained increase in alcohol consumption for more than one year could result in 19–35% additional mortality.
“Our findings highlight the need for individuals and policymakers to make informed decisions to mitigate the impact of high-risk alcohol drinking during the COVID-19 pandemic in the U.S.,” says senior author Jagpreet Chhatwal, PhD, associate director of MGH’s Institute for Technology Assessment and an assistant professor of radiology at Harvard Medical School.
“While we have projected the expected impact of societal drinking changes associated with the COVID-19 pandemic without any interventions, we hope that our research can help jumpstart needed conversations at every level of society about how we can respond to the many behavioral changes, coping mechanisms, and choices that have short- and long-term implications for the health of individuals, families and communities in America,” adds lead author Jovan Julien, MS, a data analyst at the MGH Institute for Technology Assessment and a PhD candidate at the Georgia Institute of Technology.
“The COVID-19 pandemic has had many unintended consequences with unknown long-term impact. Our modeling study provides a framework for quantifying the long-term impact of increased alcohol consumption associated with COVID-19 and initiating conversations for potential interventions,” notes co-author Turgay Ayer, PhD, the George Family Foundation Early Career Professor of Systems Engineering at Georgia Institute of Technology.
Co-authors include Elliot B. Tapper, MD, Carolina Barbosa, PhD, and William Dowd, BA.
About the Massachusetts General Hospital
Massachusetts General Hospital, founded in 1811, is the original and largest teaching hospital of Harvard Medical School. The Mass General Research Institute conducts the largest hospital-based research program in the nation, with annual research operations of more than $1 billion and comprises more than 9,500 researchers working across more than 30 institutes, centers and departments. In August 2021, Mass General was named #5 in the U.S. News & World Report list of "America’s Best Hospitals."
- Press Release
- May | 15 | 2020
A team led by researchers from Mass General has uncovered key molecular step stones in alcohol-related liver disease that may provide targets for drug therapy development.